Gossamer Bio, Inc. Common Stock
Here’s whether Gossamer Bio, Inc. Common Stock (GOSS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-34.55% over 10 days); weak 1-year return of -46.3%; 3-month momentum negative (-82.3%). Currently 88.5% off its 52-week high. Score: -6/7.
GOSS is trading below its 200-day MA ($2.12) — a key warning sign the longer-term trend is under pressure. An RSI of 67.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -46.3% compares to +35.1% for SPY (trailed the market by 81.4%). The current 88.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.